Progress and challenges in TB vaccine development. by Voss, Gerald et al.
Voss, G; Casimiro, D; Neyrolles, O; Williams, A; Kaufmann, SHE;
McShane, H; Hatherill, M; Fletcher, HA (2018) Progress and chal-
lenges in TB vaccine development. F1000Research, 7. p. 199. ISSN
2046-1402 DOI: https://doi.org/10.12688/f1000research.13588.1
Downloaded from: http://researchonline.lshtm.ac.uk/4647148/
DOI: 10.12688/f1000research.13588.1
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
 Open Peer Review
Discuss this article
 (0)Comments
REVIEW
 Progress and challenges in TB vaccine development [version 1;
referees: 2 approved]
Gerald Voss ,       Danilo Casimiro , Olivier Neyrolles , Ann Williams ,
     Stefan H.E. Kaufmann , Helen McShane , Mark Hatherill , Helen A Fletcher 9
Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands
Aeras Global TB Vaccine Foundation, Rockville, MD, 20850, USA
Sanofi Pasteur, Swiftwater, PA, 18370, USA
Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse, France
Centre for Emergency Preparedness and Response, Public Health England, Salisbury, UK
Max Planck Institute for Infection Biology, Berlin, Germany
The Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department
of Pathology, University of Cape Town, Cape Town, South Africa
London School of Hygiene & Tropical Medicine, Immunology & Infection, TB Centre, London, UK
Abstract
The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection
against tuberculosis (TB) disease, and although imperfect, BCG is proof that
vaccine mediated protection against TB is a possibility. A new TB vaccine is,
therefore, an inevitability; the question is how long will it take us to get there?
We have made substantial progress in the development of vaccine platforms, in
the identification of antigens and of immune correlates of risk of TB disease.
We have also standardized animal models to enable head-to-head comparison
and selection of candidate TB vaccines for further development.  To extend our
understanding of the safety and immunogenicity of TB vaccines we have
performed experimental medicine studies to explore route of administration and
have begun to develop controlled human infection models. Driven by a desire
to reduce the length and cost of human efficacy trials we have applied novel
approaches to later stage clinical development, exploring alternative clinical
endpoints to prevention of disease outcomes. Here, global leaders in TB
vaccine development discuss the progress made and the challenges that
remain. What emerges is that, despite scientific progress, few vaccine
candidates have entered clinical trials in the last 5 years and few vaccines in
clinical trials have progressed to efficacy trials. Crucially, we have undervalued
the knowledge gained from our “failed” trials and fostered a culture of risk
aversion that has limited new funding for clinical TB vaccine development. The
unintended consequence of this abundance of caution is lack of diversity of
new TB vaccine candidates and stagnation of the clinical pipeline. We have a
variety of new vaccine platform technologies, mycobacterial antigens and
animal and human models.  However, we will not encourage progression of
vaccine candidates into clinical trials unless we evaluate and embrace risk in
pursuit of vaccine development.
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Introduction
Tuberculosis (TB) is the leading infectious cause of death world-
wide (WHO TB report 2017). Current measures used for TB 
control are effective but insufficient. The decline in global TB 
rates remains incremental and the propensity of Mycobacterium 
tuberculosis (MTB) to develop drug resistance is a serious threat 
to our ability to control this disease with the currently avail-
able tools. Vaccination can be an effective strategy for TB 
control and it is estimated that Bacille Calmette Guerin (BCG) 
prevents 120,000 childhood deaths each year1. A TB vaccine that 
could enhance protection in infancy, or extend protection into 
adulthood, would have a significant impact on global TB rates2,3. 
In 2012 the TB vaccine community, led by the TuBerculosis 
Vaccine Initiative (TBVI) and Aeras, published a Blueprint for 
TB Vaccine Development: a global, integrated strategy, outlin-
ing major scientific challenges, critical activities and crucial 
questions4. The Blueprint summarized the current state of TB 
vaccine development and identified key areas of research critical 
for the development of a new, effective TB vaccine (Box 1).
It was envisioned that the recommendations would guide the 
next decade of TB vaccine development. This paper summa-
rizes the major advances and achievements since the publication 
of the Blueprint in 2012 and updates the critical activities and 
recommendations for accelerating TB vaccine development today.
TB vaccine technologies
A new and more effective TB vaccine is an inevitability. In TB 
there is no doubt that immunity can prevent disease and no doubt 
that protective immunity can be induced by vaccination. Evi-
dence for this includes the long lasting immune protection found 
following immunisation with BCG1,5,6 and natural immunity 
found in those latently infected with MTB7 and in those who 
either clear infection or resist disease8. The critical question 
is when a new TB vaccine will be achieved. The simple answer 
is that the more we invest in TB vaccine development the sooner 
we will have an effective TB vaccine.
Reflecting on the TB vaccine pipeline over the last 5 years, we 
see a small number of candidates that have failed at an early 
clinical stage, and some new candidates (Figure 1). Very few 
pre-clinical candidates have entered the TB vaccine pipeline 
and those in the pipeline have moved slowly through the stages 
of vaccine development or have not progressed at all (Figure 1). 
A more diverse and dynamic pipeline is needed to accelerate 
towards our goal of a new TB vaccine. We need to test a broader 
range of vaccine technologies against a broader range of antigens 
and we need to move vaccine candidates more rapidly through 
the pipeline. 
Vaccine technologies that have shown promise in pre-clinical 
studies include the cytomegalovirus (CMV) vector, which is a 
live, attenuated, persistent viral vector able to express multiple 
MTB antigens. It has been shown that the engineering of the CMV 
vector leads to constant, low-level replication of the virus, giving 
sustained antigen expression and long-term immunity, making 
this technology highly attractive for TB vaccine development9,10. 
Vaccine technologies under development for the pandemic 
flu response could also be applied to TB. One such approach 
uses mRNA as a vaccine vector11. These mRNA vaccines 
yield high level in vivo Ag expression and are relatively sim-
ple to manufacture enabling them to be tested against multiple 
pathogens with relative ease. Antibody inducing vaccines are 
underrepresented in the current TB vaccine pipeline and although 
there are many technologies available there is a need for more 
basic research in this area. It has been shown in a series of 
non-human primate (NHP) experiments that mucosal or 
intravenous vaccination with whole cell mycobacterial vaccines 
provides better protection than parenteral vaccination, by inducing 
more T helper (TH) TH17   cells, more resident memory T cells  ,12 13
and more effector T cells14.
The challenge ahead is to increase the rate at which candi-
date vaccines enter the pipeline and the rate at which candidates 
move through the pipeline (Box 2). There are promising new 
approaches, although obstacles need to be overcome for the use 
of intravenous inoculation or viral vectors which integrate into 
the host genome. Transparent and robust criteria for moving 
vaccines from one stage of vaccine development are currently 
being reviewed and will be used to increase the pace of TB vaccine 
development.
TB vaccine research and development
Novel vaccine platform technologies alone will not lead us to 
a new TB vaccine. A key activity in research and development 
is the identification of target antigens for insertion into vac-
cine candidates. In the last five years we have further developed 
the concept that MTB has distinct phases of growth, which may 
be associated with active mycobacterial replication, persist-
ence and dormancy15. Antigens associated with active bacterial 
replication include the early secreted antigens, such as the Ag85 
family, ESAT-6 and CFP-10. These antigens have been used 
extensively in TB vaccine development as they are highly 
immunogenic and have shown protection in animal models. Anti-
gens in the DosR regulon, however, are associated with dormancy 
and their use offers the possibility of designing vaccines to more 
specifically target latent MTB infection (LTBI). Most platform 
approaches used in vaccine development to date predominantly 
induce a TH1 cluster of differentiation (CD) CD4+ T cell response. 
Box 1. TB Vaccine Blueprint, 2012, recommendations
1) Technologies and discovery: A need for better 
understanding of TB disease, natural resistance, innate, T-cell 
and antibody responses and diversity in antigen discovery 
2) Preclinical models: A need for better models to predict 
efficacy in humans, for standardization, for comparability and a 
need to publish experimental failure 
3) Biomarkers and immune correlates: A need to predict 
vaccine efficacy, for use of new technologies, to understand 
the role of IFN-γ in protection and for longitudinal studies of 
correlates of risks 
4) Clinical trials and harmonization: A need for capacity 
strengthening of clinical trial sites, to determine appropriate 
endpoints, to address regulatory and ethical issues and plans for 
post licensure sustainability.
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Figure 1. The TB Vaccine Pipeline 2012–2017 (adapted from http://www.aeras.org/pages/global-portfolio).
However, in large scale screening experiments antigens that induce 
a CD8+ T cell response have been identified and can be used 
with CD8+ T cell inducing vectors to specifically boost a CD8+ 
T cell response16,17. There are also platforms and antigens that 
promote an antibody response or an unconventional T cell 
response10,18,19. The broader range in antigen choice has been 
matched with the development of novel adjuvants, including 
synthetic and bio-inspired molecules, which mimic naturally 
occurring cellular processes for more efficient delivery of vac-
cine components to the cell. The selected adjuvant can direct the 
immune response induced and the vaccine developer now has the 
option of driving immunity towards TH1, TH2, TH17 with the 
adjuvant selected20.
We now have a greater ability than ever to manipulate the 
vaccine induced immune response and this can be done at 
at least three different levels: 1) Choice of vaccine technology; 
2) Choice of antigen; 3) Choice of adjuvant. The next question 
is what type of immune response should be induced?
Our knowledge of protective immunity has greatly increased in 
the last 5 years and has broadened our awareness of the impor-
tance of the interplay between the innate and adaptive immune 
responses in TB. Correlates of risk studies have identified 
TypeI/II interferon (IFN) as a risk factor for progression to TB dis-
ease in latently infected adolescents21 and bulk T cell activation has 
been identified as a risk factor for TB in infants and adolescents22. 
These correlates of risk studies have shown that the underlying 
host immune environment plays a dominant role in TB dis-
ease risk and the impact of this environment on vaccine induced 
immunity needs to be explored. We also have a greater appre-
ciation that quality rather than quantity of T cells is important 
for function23. In addition to T cells, it is becoming more appar-
ent that B cells play an important part in immunity to TB24. 
In particular B cell function is impaired during TB and LTBI, 
which impacts cellular immunity25. Exploiting antibody-mediated 
protection against TB, and MTB dissemination in particular, has 
already shown promise in animal models26.
Despite the emergence of new technologies, whole cell myco-
bacterial vaccines remain central in TB vaccine development. 
Complexity of their antigen components including proteins, 
lipids and glycolipids allows for interaction with innate immune 
cells and induction of conventional and unconventional T cell 
responses as well as antibody responses. It has also emerged that 
BCG itself can manipulate the host immune, environment. BCG 
can induce epigenetic changes in monocytes, which enhance their 
capacity for microbial control, not only of mycobacteria but also 
against unrelated pathogens. This concept of “trained immu-
nity” is thought to result in upregulation of toll-like receptors 
and CD14 on monocytes27.
How the quality of the immune response is influenced by host 
environment, route of delivery, vaccine platform, antigen or 
adjuvant remains largely unexplored. Now that we have the 
tools to manipulate the vaccine induced immune response, we 
need to generate data sets exploring how these tools influence 
immune quality and vaccine efficacy to efficiently select the 
optimum combinations of vaccine platform, antigen and adjuvant 
for TB vaccine development (Box 2).
Phase I Phase IIa Phase IIb Phase III
Ad5 Ag85A
MCMASTER CANSINO MAX PLANCK,
VPM, TBVI, SII
SSI, TBVI, EDCTP,
INTERCELL
TBVI, ZARAGOZA,
BIOFABRI
IDRI, AERAS
CRUCELL, OXFORD,
AERAS
CRUCELL, AERAS
MTBCAC
ID93 + GLA-SE
Crucell Ad35 /
MVA85A
VPM 1002
13 Candidates
4/6/2/1
13 Candidates
5/4/3/1
MVA85A /
AERAS-485
H1 + IC31
RUTI
ARCHIVAL FARMA, S.L
H4 / AERAS-404 +
IC31
SSI, SANOFI-PASTEUR,
AERAS, INTERCELL
H56 / AERAS-456 +
IC31
Crucell Ad35 /
AERAS-402
SSI, AERAS, INTERCELL
OXFORD, AERAS
ANHUI LONGCOM, CHINA
GSK, AERAS
M72 + AS01E
M. Vaccae
MTBVAC RUTI DAR-901
VPM 1002
M72 + AS01E
H1/H56: IC31
H4: IC31
ID93 + GLA-SE
Ad5 Ag85A
TB/FLU-04L
ChAdOx1.85A/MVA85A
MVA85A/MVA85A(ID, Aerosol)
Phase 1 Phase 2a Phase 2b Phase 3
Biofabri, TBVI, Zaragosa
McMaster, CanSino
Oxford, Birmingham
Oxford
Archivel Farma, S.L
SSI, Valneva, Aeras
Sanofi Pasteur, SSI, Aeras
IDRI, Wellcome Trust
RIBSP
Dartmouth Anhui Zhifei Longcom
GSK, Aeras
SII, Max Planck, VPM, TBVI
Vaccae™
AERAS Advancing TuberculosisVaccines for the World
Viral Vector
Protein / Adjuvant
Mycobacterial – Whole Cell or Extract
Revised on February 2, 2017
Please note: Information is self-reported by vaccine sponsors
TB Vaccine Pipeline 2012 TB Vaccine Pipeline 2017
Page 4 of 14
F1000Research 2018, 7:199 Last updated: 21 MAR 2018
Box 2. Conclusions and recommendations
TB vaccine technologies
•	 The global TB vaccine community should unite to maintain a dynamic vaccine candidate pipeline from discovery to late stage.
• There are currently no unanimously agreed criteria for advancing vaccine candidates.
TB vaccine research and development
•	 	Future discovery efforts should include investigation of immune quality and vaccine efficacy in response to combinations of 
vaccine platform, antigen and adjuvant.
• The evaluation of host factors impacting protection should be included in future scientific investigation.
• Whole cell mycobacterial vaccines should continue to be central to TB vaccine development.
The role of animal models
•	 Animal models and clinical studies should progress in parallel and may offer opportunities for cross-validation.
• The most appropriate animal models should be selected based on evidence and the underlying question(s) to be answered.
•  The use of multiple different animal models can have a cumulative value in assessing vaccine candidates or answering 
pathogenesis questions.
• There is an opportunity for the funders to encourage further standardization of models.
•  An obligation to publish animal studies regardless of the outcome (as it is the case for clinical trials) should be encouraged and 
would facilitate vaccine development.
Biomarkers, Systems Biology and immune correlates
•	 	The approach to biomarkers should remain broad, looking at correlates of safety, risk of stable infection or disease, and vaccine 
efficacy.
• Observational studies will help to identify biomarkers of risk of infection or disease.
• Interventional (vaccine) studies and observational studies should be used to create and expand biobank repositories.
Experimental medicine and human challenge
•	 A space for clinical research studies needs to be maintained and expanded.
• A favourable regulatory environment is critical for the conduct of clinical research studies and should be advocated for.
•  Investment into the establishment of controlled human TB challenge models needs to continue. Learnings from the malaria field 
should be integrated in this process and synergies with biomarker research needs to be created.
Clinical and late stage development
•	 We need to keep (pipeline) diversity at all levels since we still wait for a clear efficacy signal.
• De-risking candidates through gating criteria does not mean being risk-adverse.
•  We need to evaluate and accept some risk but prepare carefully and perform high quality studies which can advance the field 
even in the absence of an efficacy signal.
The role of animal models
There are several different animal models that are used in the 
TB vaccine development pipeline and these are useful from the 
discovery phase right through to advanced pre-clinical devel-
opment. Animal models are currently perceived as key for 
demonstration of safety during all stages of development and 
immunogenicity during early screening, and informative for 
demonstration of a protective effect against MTB challenge.
Systematic screening in animal models can thus be used to 
select vaccine candidates that achieve a threshold of safety, 
immunogenicity and efficacy. There is also the ability to perform 
comparative head-to-head testing in independent laboratories, 
for prioritization of the most promising vaccine candidates. Mice, 
guinea pigs and NHP are the most commonly used species for 
vaccine testing and study designs vary depending on the 
animal species, the type of vaccine and the rationale for 
demonstrating efficacy (e.g. reducing bacterial burden, 
prolonging survival or preventing reactivation). This complex-
ity in species and study design attempts to reflect complexity of 
human disease, but it means that there is no single, harmonized 
animal model that could be used for clear ‘go / no-go’ decisions 
for candidate TB vaccines. However, there is greater confidence 
in data that show the efficacy of a candidate in multiple in vivo 
systems, particularly when those studies are conducted in 
independent laboratories.
There has been considerable progress in animal models since 
the 2012 blueprint. There is an improved understanding of 
the strengths and weaknesses of the different models28–30 and 
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greater recognition of the need for ‘fit-for-purpose’ study designs 
to achieve robust, quantifiable measures of efficacy. Animal 
data are now available for many TB vaccine candidates, some 
of which are undergoing clinical testing. In all cases the degree 
of protection of the novel vaccines relative to the controls 
(unvaccinated or BCG), although statistically significant, is 
not substantial. More clinical efficacy data are needed to know 
whether this level of protection in animals is predictive of an 
efficacy signal in humans; this information is needed urgently 
to provide biological validity of the animal models and to estab-
lish whether existing animal models and study designs need to 
be refined28. There are also efforts to develop models reflective 
of the more complex environment of target populations. These 
include infant animal models for neonatal vaccines; post-
MTB exposure vaccination; models of co-morbidities, such as 
diabetes and HIV infection; and models that involve natural 
transmission of the pathogen.
Data from animal models have become increasingly important 
to the Stage Gating processes, which aim to assist developers 
and funders to accelerate candidates from discovery through 
pre-clinical development. However, negative results are not 
always reported in the public domain, and therefore the full 
value of these data to enable lessons to be learnt, has not been 
realized. Some funders have set requirements for efficacy in 
NHP to be demonstrated before clinical testing, which high-
lights the need for stringent thresholds and harmonization in 
terms of read-outs of vaccine efficacy. An absolute requirement 
for statistically robust efficacy in NHP is, however, costly and 
difficult due to limitations of space and animal availability and 
must be balanced against the cost of collecting data in humans.
Biomarkers, Systems Biology and immune correlates
Success in studies of individuals with LTBI and active TB 
patients has led to host biomarkers becoming an integral part 
of future TB control. Proof of principle has been given that 
biomarkers can distinguish between active TB disease and 
LTBI, and evidence is accumulating that biomarkers can predict 
progression to active TB31. Thus, it has been demonstrated 
that small-sized biosignatures comprising 3-4 transcripts are 
capable of reliably discriminating TB disease from LTBI and 
medium-sized biosignatures comprising 16 transcripts or less 
allow prediction of active TB by diagnosing incipient, 
subclinical TB21.
Beyond their application for diagnosis, biomarkers can pro-
vide important contributions to the clinical development of 
vaccines against TB (Figure 2)32. First, individuals with sub-
clinical TB may benefit from preventive TB drug treatment. 
Second, such biosignatures allow stratification of individu-
als with subclinical TB for clinical vaccine trials to reduce 
participant numbers and shorten trial duration. Moreover, such 
biosignatures will serve as valuable tools for monitoring of clini-
cal trial participants. Although they will not replace the clinical 
endpoints, early recognition of progression to active TB will 
provide valuable information.
Whilst most biosignatures defined thus far were derived from 
observational studies on contacts and TB patients, future stud-
ies must focus on biosignatures of vaccine efficacy, although 
these can only be derived when we have a vaccine which 
demonstrates efficacy in clinical trials. In the meantime, infor-
mation can be obtained from observational studies on BCG 
vaccination in infants. It has, for example, been shown that there 
is a lower risk of progression to TB disease in BCG vaccinated 
infants with either a higher INF-γ ELISpot response against 
mycobacterial antigens or higher Ag85A IgG antibody levels22.
Design of biosignatures of vaccine efficacy needs to consider 
the following groups: individuals who develop active TB despite 
being vaccinated (vaccine failure), individuals who remain healthy 
because of vaccination, individuals who remain healthy due 
to natural resistance (independent of vaccination).
Finally, biosignatures can inform about the mechanisms under-
lying pathogenesis and protection, paving the way for in-depth 
analysis of the biological functions of differentially regulated 
biomarkers. For example, correlates of risk studies, performed 
using samples collected during the MVA85A vaccine efficacy trial, 
have revealed that T cell activation and CMV infection are asso-
ciated with future risk of developing TB disease22,33. Deeper 
understanding of the factors that drive TB risk will facilitate 
the design of next-generation vaccine candidates. 
Integration of biosignatures into clinical trial design will add 
cost; however, it is critical that we take every opportunity to add 
value to clinical studies. Biosignatures will be of great value 
for refining the vaccine candidate tested and for developing 
alternative vaccine types and modes of immunization.
Experimental medicine and human challenge
Clinical trials are an essential part of the product development 
pathway for TB vaccine development. However, restricting the 
conduct of clinical trials to product development ignores the 
utility of experimental medicine studies to generate novel sci-
entific insights. Experimental medicine can be defined as ‘an 
investigation undertaken in humans, relating where appropriate 
to model systems, to identify mechanisms of pathophysiology 
or disease, or to demonstrate proof-of-concept evidence of 
the validity and importance of new discoveries or treatments’. 
Experimental medicine and product development are not mutu-
ally exclusive. A vaccine could be tested to both address a 
proof-of-concept experimental medicine question and in par-
allel be a critical step in a product development pathway. An 
example of this is the first-in-class testing of an attenuated strain 
of MTB as a potential vaccine candidate34. Furthermore, can-
didate vaccines could move between experimental medicine 
and product development, this flexibility is important as we 
are still at the frontiers of knowledge in TB vaccine clini-
cal testing. There are many examples of small scale, phase I 
experimental medicine studies which have provided valuable 
information on safety and immunogenicity, such as the testing 
of combination vaccine approaches35 and the testing of novel 
routes of delivery, e.g. aerosol36.
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Human challenge models are the ultimate in experimental medi-
cine studies. In such studies, healthy vaccinated volunteers 
are intentionally inoculated with the pathogen in question, to 
allow the efficacy of a candidate vaccine to be evaluated in a 
small-scale study prior to embarking on expensive field efficacy 
trials. Such controlled human challenge models have been game 
changing in malaria vaccine development37. However, unlike 
malaria, and other human challenge models in clinical use, we 
cannot deliberately infect human subjects with virulent MTB 
for obvious ethical reasons. Efforts to develop a controlled 
human mycobacterial challenge model using BCG, or attenuated 
strains of MTB, are underway38,39. Ultimately, human challenge 
models need validation against field efficacy studies. However, 
they can also be corroborated against a known vaccine effect in 
preclinical animal models38.
There is an underexploited role for experimental medicine in 
TB vaccine development, in parallel with product development, 
in early and late (efficacy) trials. We need innovative ways to 
demonstrate an efficacy signal in humans with TB vaccine 
candidates. Controlled human mycobacterial infection studies 
offer a potential way to achieve this. Such studies, if they were to 
demonstrate a biological signal, would allow the prioritiza-
tion of candidates for progression to prevention of disease 
studies. The predictive value of human immunology, animal 
models, and these surrogate efficacy endpoints can only be deter-
mined by progressing some candidates to field efficacy studies. 
There is no substitute for human efficacy testing against disease 
in the development of an effective TB vaccine. Consider-
able information can be gained from efficacy trials regardless 
of the efficacy results22. Repeated cycles of iteration between 
animal and human studies will yield important insights and 
advance the development of an effective vaccine.
Clinical and late stage development
Experimental medicine studies are not confined to early phase 
clinical vaccine trials and human challenge studies, they are 
also being used to make TB vaccine efficacy trials faster, shorter 
Figure 2. Role of biomarkers in TB vaccine development. This figure has been reproduced with permission from Kaufmann, Evans, 
Hanekom, Science Transl. Med., 201532.
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and more cost-effective. This is achieved by leveraging the 
much higher incidence rates of MTB infection as measured by 
interferon-γ release assays (IGRA) conversion for preven-
tion of infection studies (POI) and measurement of TB 
recurrence after treatment for prevention of recurrence studies 
(POR). The incidence rates of infection and recurrence are much 
higher when compared to community-based incident TB disease 
so clinical trials with POI and POR endpoints can be smaller and 
faster than those with a disease endpoint (POD). POI and POR 
trials have rapidly gained acceptance as a pathway to demon-
strate proof-of-concept prior to large-scale efficacy trials40,41. 
In South Africa, annual IGRA conversion rates of 6–7% in 
infants42 and up to 14% in adolescents43 have been reported; and 
TB disease recurrence rates are estimated at 2–5% for standard 
of care TB treatment arms in a clinical trial setting. These rates 
are very compelling, in terms of endpoint accrual, compared 
to the 0.78% annual incidence of TB disease estimated among 
South African adults by the World Health Organization. As a 
result, POI trials have been initiated to test the booster vaccines 
H4 (NCT02075203) and DAR-901 (NCT02712424).
The VPM1002 vaccine is being tested in a phase II/III POR 
trial (NCT03152903) in adults with cured TB and expects a 
10% rate of recurrence (relapse or reinfection) over a 12 month 
period of follow-up.
Bridging from e.g. a POI trial to POD trial in the same popula-
tion presents a very real challenge. Using the high TB inci-
dence South African example to illustrate the most cost-effective 
clinical trial scenario, average incidence of microbiologi-
cally confirmed TB disease in adolescents (incidence 0.43%) is 
almost half that in adults44. Therefore, a POD trial for the iden-
tical population in whom POI might be demonstrated as proof 
of concept would be large, long and costly. Curiously, even 
though childhood TB is notoriously paucibacillary, it might be 
more efficient to conduct a POD trial in newborn infants, the 
only IGRA- population that is not also exposed to other myco-
bacteria, including BCG, even if the TB disease endpoint were 
limited to microbiologically confirmed disease (incidence 0.7%)42.
TB vaccine development efforts are increasingly focused on pre-
vention of pulmonary TB disease in adolescents and adults, to 
block the MTB transmission cycle. The majority of adults in 
TB endemic countries like South Africa are IGRA+45, mak-
ing POD trials in IGRA+ adults more feasible since rates 
of disease are higher, yet based on our knowledge of histori-
cal BCG trials, IGRA+ (and previously BCG vaccinated) adult 
populations are likely to pose the biggest challenge to demonstrate 
additional vaccine efficacy46.
Progression of a TB vaccine candidate to POD or a proof-of-concept 
POI or POR trial is therefore not simply contingent upon 
application of product development Stage Gate criteria, but a 
complex consideration of vaccine target population, endpoint 
accrual, operational efficiency - and most importantly – cost. 
If we consider the TB vaccine pipeline in 2012 (Figure 1), 
which included four vaccines in Phase 1, six in Phase 2, and 
three in efficacy trials, compared to the five vaccines in Phase 1, 
four in Phase 2, and four in efficacy trials in 2017 (Figure 1), 
the pipeline appears healthy. However, with few exceptions, 
most candidates have not progressed through the pipeline in the 
last five years. It is notable that of the seven candidates now in 
Phase 2, current and planned clinical trial activity includes three 
POI and three (pilot safety and immunogenicity or efficacy) 
POR trials, which raises the question of why experimental medi-
cine strategies intended to supplement the traditional product 
development pathway have instead replaced traditional safety 
and immunogenicity, and safety and efficacy trials, to such 
a large extent. We speculate that the wholesale shift towards 
experimental medicine strategies is a manifestation of a lim-
ited funding environment, which has forced developers to 
adopt more cost-effective approaches to vaccine testing. One 
major disadvantage to cost-effective experimental medicine 
approaches is that we do not know if prevention of infection will 
result in prevention of disease. Reciprocally, it is possible that 
prevention of disease could be achieved with a vaccine that 
had no impact on infection and POI trials would triage out 
such candidates. Success of a vaccine candidate in a POI or 
POR trial would likely accelerate clinical development, but 
should failure in an experimental medicine trial halt progression 
in the traditional development pathway?
It also appears that the number and diversity of new TB vaccine 
candidates entering clinical trials has become increasingly lim-
ited, which might severely restrict the options to develop new 
TB vaccines aimed at a wide target spectrum of age (infants, 
adolescents, adults or the elderly), MTB exposure status 
(IGRA+, IGRA-), and indication (POD, POR and therapeutic). 
No matter how promising an individual candidate may appear 
in pre-clinical studies, it would be high risk to commit resources 
only to development of a single candidate, which inevitably car-
ries some risk of failure when safety, immunogenicity and 
efficacy are tested in humans. This consideration is perhaps most 
relevant to the highest priority of protecting previously BCG 
vaccinated, MTB-infected adults against progression to active 
TB disease.
Therefore, we propose that diversity is an essential qual-
ity of a healthy TB vaccine pipeline that will ultimately lead 
to a successful vaccine, or vaccines, that meet the needs of a 
variety of susceptible populations, including adults, children 
and HIV-infected persons living in TB endemic countries. If we 
accept this premise, it follows that we must accept the 
inevitable possibility of failure of individual candidates, or spe-
cific trial designs, to meet acceptable standards when tested 
for safety, immunogenicity or efficacy in human populations. 
We want to accept risk, after serious evaluation of all issues 
including biological, medical, ethical and legal aspects. We 
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need not fear failure, since progression in our field depends 
on our willingness to evaluate and accept risk, provided that 
we learn from each clinical trial, and collect and store suffi-
cient data and samples to improve future chances of success. 
Perhaps the most illustrative example of ‘failing well’ is 
the infant trial of the MVA85A candidate, which conclu-
sively failed to demonstrate added protection to that provided 
by newborn BCG vaccination, but taught invaluable lessons 
about conduct of infant vaccine trials42,47–49, pre-clinical animal 
models28, community engagement47, endpoint determination50,51, 
and biomarkers of risk for TB22,52.
We propose that logical application of Stage Gate criteria to de-
risk and progress a number of diverse vaccine candidates through 
human trials, in the knowledge that most will fail, is a necessary 
and efficient strategy to achieve the ultimate goal of a successful 
TB vaccine. This approach does carry the responsibility, not only 
to learn iteratively from past failures, but to be prepared to adapt 
rapidly and decisively in the face of new data. We advocate for 
empiric advancement of promising candidates into clinical trials, 
in parallel with iterative studies to better understand risk for and 
protection against TB. Conversely, we propose that application 
of our field’s limited global resources to development of only a 
small number of very carefully selected candidates, no matter 
how promising, would lead to a shrinking, less diverse pipeline, 
increasingly vulnerable to the consequences of failure. In that con-
text, excessive risk-aversion is itself a high-risk strategy, given the 
urgency for a new vaccine to impact on global burden of disease.
Conclusions
This paper reviewed progress made in TB vaccine development 
since the initial Blueprint for the field was published in 2012. 
Then and now, a TB vaccine is inevitable to put an end to TB. As 
for many other infectious diseases, a safe, efficacious and afford-
able vaccine is an essential part of the solution. Getting there 
will not be easy, and tremendous progress has been made dur-
ing the last five years. The TB vaccine community now has at 
its disposal a broad portfolio of platform technologies, vaccine 
antigens and insight into immunological mechanisms that can 
be leveraged to expedite TB vaccine development. However, the 
global TB vaccine pipeline has progressed much less than desired 
in recent years, and we hope that the new tools and insights 
from technologies and discovery research will feed into a rich 
and diverse pipeline in the future. Animal models will be vital 
to swiftly advance novel vaccine candidates into clinical trials. 
While the predictive value of animal models can ultimately only be 
validated by human efficacy data, the evaluation of vac-
cine candidates in a combination of rationally selected animal 
models provides an early gauge and Stage Gate. Similarly 
helpful in moving vaccines through the development path are 
biomarkers and immune correlates. Biomarker technology 
has matured enormously over the last five years, yielding tests 
that are ready to support pre-clinical and clinical development. 
Further validation of promising biomarkers could come from 
experimental medicine studies (including a human mycobacte-
rial challenge model) and from larger clinical trials with an effi-
cacy endpoint. Continued clinical research as well as advanced 
large scale field studies will be critical to validate animal models 
and biomarkers, establish proof of scientific concepts, and will 
ultimately yield an efficacy signal that the entire field is waiting 
for. We cannot afford to relent in this effort and must be willing 
to invest wisely, knowing that many trials will fail. Acceptance of 
risk and failure is an integral part of developing vaccines and the 
potential global public health impact of an effective vaccine 
should encourage us to continue to invest our intellectual and 
financial capital in TB vaccine development.
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